[go: up one dir, main page]

MX2022006045A - Metodos de administracion de voxelotor. - Google Patents

Metodos de administracion de voxelotor.

Info

Publication number
MX2022006045A
MX2022006045A MX2022006045A MX2022006045A MX2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A
Authority
MX
Mexico
Prior art keywords
voxelotor
methods
administering
avoiding
inhibitor
Prior art date
Application number
MX2022006045A
Other languages
English (en)
Inventor
Carla B Washington
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of MX2022006045A publication Critical patent/MX2022006045A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente métodos de uso de voxelotor para el tratamiento de la enfermedad de células falciformes en pacientes que también tienen insuficiencia hepática grave. También se proporcionan en la presente métodos para administrar voxelotor y evitar o disminuir las interacciones farmacológicas adversas con un inductor o inhibidor de CYP3A4. También se proporcionan en la presente métodos para evitar interacciones con voxelotor, un inhibidor moderado de CYP3A4.
MX2022006045A 2019-11-19 2020-11-17 Metodos de administracion de voxelotor. MX2022006045A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937706P 2019-11-19 2019-11-19
US201962940154P 2019-11-25 2019-11-25
PCT/US2020/060923 WO2021101910A1 (en) 2019-11-19 2020-11-17 Methods of administering voxelotor

Publications (1)

Publication Number Publication Date
MX2022006045A true MX2022006045A (es) 2022-08-15

Family

ID=73835728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006045A MX2022006045A (es) 2019-11-19 2020-11-17 Metodos de administracion de voxelotor.

Country Status (7)

Country Link
US (1) US20230015823A1 (es)
EP (1) EP4061368A1 (es)
BR (1) BR112022009522A2 (es)
CA (1) CA3161761A1 (es)
IL (1) IL292982A (es)
MX (1) MX2022006045A (es)
WO (1) WO2021101910A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081801A2 (en) * 2021-11-05 2023-05-11 Global Blood Therapeutics, Inc. Methods of administering voxelotor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171665T1 (hr) 2011-12-28 2017-12-15 Global Blood Therapeutics, Inc. Supstituirani spojevi benzaldehida i metode za njihovu primjenu u povećanju oksigenacije tkiva
SMT202100160T1 (it) 2014-02-07 2021-05-07 Global Blood Therapeutics Inc Polimorfo cristallino della base libera di 2-idrossi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metossi)benzaldeide
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑

Also Published As

Publication number Publication date
IL292982A (en) 2022-07-01
CA3161761A1 (en) 2021-05-27
WO2021101910A1 (en) 2021-05-27
US20230015823A1 (en) 2023-01-19
BR112022009522A2 (pt) 2022-08-16
EP4061368A1 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2020003351A (es) Metodos, composiciones y elementos implantables que comprenden celulas activas.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
CL2019003496A1 (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2024008461A (es) Metodos para tratar trastornos linfoproliferativos malignos.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
MX390722B (es) Tratamiento de resistencia a diureticos.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2022006045A (es) Metodos de administracion de voxelotor.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
MX2021013351A (es) Terapias de combinacion.
MX2018010096A (es) Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos.
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease